Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 13/20 | 0.54 |
| ▸ | CTSK | P43235 | 10/20 | 0.52 |
| ▸ | CTSS | P25774 | 8/20 | 0.50 |
| ▸ | CTSB | P07858 | 7/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2156197 | 0.87 | CTSL (0.71) | CTSLCTSKCTSSCTSB | |
| SCHEMBL4955135 | 0.86 | CTSL (0.56) | CTSLCTSKCTSSCTSB | |
| SCHEMBL2155284 | 0.86 | CTSL (0.54) | CTSLCTSKCTSSCTSB | |
| SCHEMBL14673619 | 0.84 | CTSL (0.74) | CTSLCTSKCTSSCTSB | |
| SCHEMBL4952733 | 0.83 | CTSK (0.65) | CTSLCTSKCTSSCTSB | |
| SCHEMBL2157089 | 0.82 | CTSL (0.58) | CTSLCTSKCTSSCTSB | |
| SCHEMBL14673131 | 0.82 | CTSL (0.62) | CTSLCTSKCTSSCTSB | |
| SCHEMBL2156135 | 0.81 | CTSL (0.57) | CTSLCTSKCTSSCTSB | |
| SCHEMBL14673469 | 0.80 | CTSL (0.59) | CTSLCTSKCTSSCTSB | |
| SCHEMBL14673156 | 0.80 | CTSL (0.59) | CTSLCTSKCTSSCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080188529-A1 | N1-(cyanomethyl)-N2-(2,2,2-trifluoro-1-phenylethyl)-L-leucinamide; antiarthritic agent; osteoporosis and other bone loss disorders | MERCK CANADA INC. (CA) | 2008-08-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188529-A1 | N1-(cyanomethyl)-N2-(2,2,2-trifluoro-1-phenylethyl)-L-leucinamide; antiarthritic agent; osteoporosis and other bone loss disorders | CTSE, CTSL, CTSK | CTSL 2/4885CTSK 3/4885CTSS 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.